Business Context and Reporting Period
Alterity Therapeutics Limited, a development-stage enterprise headquartered in Melbourne, Australia, filed a Form 6-K as a foreign private issuer for September 2026. The filing was signed on September 23, 2026, and references the company’s September 2026 corporate presentation as Exhibit 99.1.
The company files annual reports on Form 20-F. The filing is incorporated by reference into specified Form S-8 and Form F-3 registration statements.
Financial Metrics and Capitalization
The filing text does not provide clear values for revenue, profit or loss, cash flow, operating margins, debt, liquidity, cash balances, or other financial metrics. No financial statements are included in the provided text.
Material Changes Versus Prior Period
The filing text does not describe material changes versus a prior comparable period. The referenced corporate presentation may contain additional information, but its contents were not provided.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide guidance, financial outlook, management commentary, risk disclosures, contingencies, or unusual items. It identifies Alterity as a development-stage enterprise, but does not provide additional operating or clinical details.
Investor Verification Items
- Review Exhibit 99.1, the September 2026 corporate presentation, for operational, clinical, financing, and strategic updates.
- Verify the company’s cash runway, funding requirements, and any planned capital raises in subsequent filings.
- Review the latest Form 20-F and interim financial disclosures for revenue, expenses, losses, cash flow, liquidity, and commitments.
- Confirm whether any material developments occurred after the September 23, 2026 filing date.